V3-specific neutralizing antibodies in sera from HIV-1 gp160-immunized volunteers block virus fusion and act synergistically with human monoclonal antibody to the conformation-dependent CD4 binding site of gp120. NIH-NIAID AIDS Vaccine Clinical Trials Network.

@article{Montefiori1993V3specificNA,
  title={V3-specific neutralizing antibodies in sera from HIV-1 gp160-immunized volunteers block virus fusion and act synergistically with human monoclonal antibody to the conformation-dependent CD4 binding site of gp120. NIH-NIAID AIDS Vaccine Clinical Trials Network.},
  author={D. Montefiori and B. Graham and J. Zhou and R. A. Bucco and D. Schwartz and L. Cavacini and M. Posner},
  journal={The Journal of clinical investigation},
  year={1993},
  volume={92 2},
  pages={
          840-7
        }
}
Sera from 11 volunteers immunized with a recombinant HIV-1 gp160-expressing vaccinia virus (HIVAC-1e; Oncogen/Bristol-Myers Squibb, Seattle, WA) and boosted with baculovirus-derived rgp160 (VaxSyn; MicroGeneSys, Inc., Meriden, CT) were evaluated for functional serum antibodies and their epitopes. Sera obtained prior to boosting had undetectable HIV-1-specific IgG and neutralizing activity, and did not block HIV-1 from binding or fusing to CD4+ MT-2 cells. 14 d after boosting, sera from each… Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 33 REFERENCES
Evidence for non-V3-specific neutralizing antibodies that interfere with gp120/CD4 binding in human immunodeficiency virus 1-infected humans.
  • C. Kang, P. Nara, +5 authors H. Köhler
  • Biology, Medicine
  • Proceedings of the National Academy of Sciences of the United States of America
  • 1991
Restricted neutralization of divergent human T-lymphotropic virus type III isolates by antibodies to the major envelope glycoprotein.
...
1
2
3
4
...